Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
Authors
Keywords
Catalytic spine, Hydrophobic interaction, Protein kinase inhibitor classification, Protein kinase structure, Regulatory spine, Shell residues
Journal
PHARMACOLOGICAL RESEARCH
Volume -, Issue -, Pages 105422
Publisher
Elsevier BV
Online
2021-01-12
DOI
10.1016/j.phrs.2021.105422
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Colorectal cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Zanubrutinib: First Approval
- (2020) Yahiya Y. Syed DRUGS
- Molecular epidemiology and diagnostics of KRAS mutations in human cancer
- (2020) Jozsef Timar et al. CANCER AND METASTASIS REVIEWS
- KRAS: From undruggable to a druggable Cancer Target
- (2020) Dipesh Uprety et al. CANCER TREATMENT REVIEWS
- Approaches to mitigate the risk of serious adverse reactions in covalent drug design
- (2020) Thomas A. Baillie Expert Opinion on Drug Discovery
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- (2020) Yi-Long Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options
- (2020) Simon Peter Gampenrieder et al. Cancer Management and Research
- Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies
- (2020) Alexey V. Danilov et al. BRITISH JOURNAL OF HAEMATOLOGY
- Management of Waldenström macroglobulinemia in 2020
- (2020) Jorge J. Castillo et al. Hematology-American Society of Hematology Education Program
- A Practical Review of Proteasome Pharmacology
- (2019) Tiffany A. Thibaudeau et al. PHARMACOLOGICAL REVIEWS
- Acalabrutinib for Mantle Cell Lymphoma
- (2019) Thomas E Witzig et al. BLOOD
- Management of adverse effects/toxicity of ibrutinib
- (2019) Semra Paydas CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Targeting ERK1/2 protein-serine/threonine kinases in human cancers
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
- (2019) Pawel Robak et al. Drugs in research & development
- Zanubrutinib in B-cell malignancies
- (2019) Manjulika Das LANCET ONCOLOGY
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Landscape of Atypical and Eukaryotic Protein Kinases
- (2019) Georgi K. Kanev et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
- (2018) Harpreet Singh et al. CLINICAL CANCER RESEARCH
- Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation–positive advanced non-small-cell lung cancer
- (2018) S. Morin-Ben Abdallah et al. Current Oncology
- Progress with covalent small-molecule kinase inhibitors
- (2018) Zheng Zhao et al. DRUG DISCOVERY TODAY
- Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
- (2018) Tony S. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
- (2018) Yoshihisa Kobayashi et al. Journal of Thoracic Oncology
- PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials
- (2018) Fabrice Carles et al. MOLECULES
- Kinase inhibitors: the road ahead
- (2018) Fleur M. Ferguson et al. NATURE REVIEWS DRUG DISCOVERY
- Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
- (2018) Robert Roskoski et al. PHARMACOLOGICAL RESEARCH
- The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease
- (2018) Maximilian Hochmair Targeted Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Acalabrutinib and its use in treatment of chronic lymphocytic leukemia
- (2018) Yasir Khan et al. Future Oncology
- Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology
- (2018) Matthias Gehringer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pharmacological targeting of RAS: Recent success with direct inhibitors
- (2018) John P. O’Bryan PHARMACOLOGICAL RESEARCH
- Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Guidelines for preparing color figures for everyone including the colorblind
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Targeted Covalent Inhibitors for Drug Design
- (2016) Thomas A. Baillie ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family
- (2016) Jeff B. Smaill et al. JOURNAL OF MEDICINAL CHEMISTRY
- Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions
- (2016) Paul A. Jackson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview
- (2016) Peter M. Fischer MEDICINAL RESEARCH REVIEWS
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management
- (2015) Morie A. Gertz AMERICAN JOURNAL OF HEMATOLOGY
- FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
- (2015) R. A. de Claro et al. CLINICAL CANCER RESEARCH
- Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
- (2015) Yuliana Yosaatmadja et al. JOURNAL OF STRUCTURAL BIOLOGY
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- A historical overview of protein kinases and their targeted small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
- (2015) Sai-Hong Ou et al. Drug Design Development and Therapy
- Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
- (2015) Alexandra Canonici et al. Oncotarget
- Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
- (2014) M. Raymond V. Finlay et al. JOURNAL OF MEDICINAL CHEMISTRY
- Vane’s discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology
- (2014) Regina M. Botting Pharmacological Reports
- ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
- (2014) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
- (2013) Qingsong Liu et al. CHEMISTRY & BIOLOGY
- The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders
- (2013) Robert Roskoski Expert Opinion on Drug Discovery
- KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space
- (2013) Oscar P. J. van Linden et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ErbB/HER family of protein-tyrosine kinases and cancer
- (2013) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Proton Pump Inhibitors in Pediatrics
- (2013) Robert M. Ward et al. PEDIATRIC DRUGS
- Deciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
- (2013) Hiruy S. Meharena et al. PLOS BIOLOGY
- New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
- (2012) Vandana Lamba et al. CURRENT PHARMACEUTICAL DESIGN
- Treatment of Older Patients with Mantle-Cell Lymphoma
- (2012) H.C. Kluin-Nelemans et al. NEW ENGLAND JOURNAL OF MEDICINE
- ERK1/2 MAP kinases: Structure, function, and regulation
- (2012) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
- (2012) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
- (2011) Arvin C. Dar et al. Annual Review of Biochemistry
- Monoamine Oxidase B Inhibitors for the Treatment of Parkinsonʼs Disease
- (2011) Anthony H.V. Schapira CNS DRUGS
- Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent Inhibitors
- (2011) Emeline Leproult et al. JOURNAL OF MEDICINAL CHEMISTRY
- The resurgence of covalent drugs
- (2011) Juswinder Singh et al. NATURE REVIEWS DRUG DISCOVERY
- RAF protein-serine/threonine kinases: Structure and regulation
- (2010) Robert Roskoski BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
- (2009) Fabio Zuccotto et al. JOURNAL OF MEDICINAL CHEMISTRY
- Lung Cancer
- (2008) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- A helix scaffold for the assembly of active protein kinases
- (2008) A. P. Kornev et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now